The Impact of Systolic Blood Pressure Control in Angiotensin II Antagonist Blockade

Hansson L

Homepage:
www.kup.at/jcbc

Online Data Base Search for Authors and Keywords
The Impact of Systolic Blood Pressure Control in Angiotensin II Antagonist Blockade

L. Hansson

Elevated systolic blood pressure is nowadays recognized as an even stronger predictor than elevated diastolic blood pressure of cardiovascular morbidity and mortality. Even borderline isolated systolic hypertension is associated with significant increases in cardiovascular risks. Moreover, large prospective intervention trials on the treatment of patients with isolated systolic hypertension have shown significant reductions in the risks of stroke and coronary heart disease. In this perspective it is of interest to note that the new angiotensin II receptor antagonist, the AT1 receptor selective agent eprosartan, has been shown to effectively reduce systolic blood pressure, both in patients with severe hypertension as well as in other patient groups. J Clin Basic Cardiol 2001; 4: 131–134.

Key words: systolic hypertension, cardiovascular morbidity, angiotensin II receptor blockade, eprosartan

A clinically useful way of measuring blood pressure with a sphygmomanometer was introduced in 1896 by Riva-Rocci (Figure 1). By palpating the pulse distal to the cuff, ie usually the pulse in the radial artery, it was possible to assess the systolic blood pressure. In 1905 Korotkoff pioneered the technique of measuring also the diastolic blood pressure by applying a stethoscope to the artery distal to the cuff, ie usually the brachial artery. Following this development it became gradually more fashionable to measure the diastolic blood pressure and in a number of the early intervention trials, such as the Veterans Administration Study and others, the diastolic blood pressure was the main criterion for the definition of hypertension and the target of treatment (Table 1) [1–8].

In more recent years the Hypertension Optimal Treatment (HOT) study used the diastolic blood pressure for the randomization of patients to one of three treatment targets, a diastolic blood pressure of ≤ 90, ≤ 85 or ≤ 80 mmHg [9].

Another reflection of the widespread dependence on diastolic blood pressure in the area of hypertension is the fact that most guidelines for the management of hypertension only provided definitions based on the diastolic blood pressure. As an example: the 1989 recommendations for the management of mild hypertension from the World Health Organization and the International Society of Hypertension (WHO/ISH) stated “No evidence is yet available on the benefits of lowering the systolic blood pressure” [10].

The Growing Importance of Systolic Blood Pressure

As briefly reviewed above, for several decades the scientific and clinical interest in hypertension was focused on the diastolic blood pressure. This may seem surprising for several reasons. It is, for example, technically more difficult to accurately measure the diastolic than the systolic blood pressure when using the Riva-Rocci and Korotkoff non-invasive technique with a sphygmomanometer and a stethoscope. It is conceivable that doctors during the 1920s, when the Korotkoff technique became more widely employed, were so excited by this new possibility to measure the diastolic blood pressure that the sheer aspect of novelty resulted in a relative over-emphasis of the importance of the diastolic blood pressure.

There are obviously other reasons as well. Over the years most textbooks on cardiology and internal medicine have presented and emphasized the view that it was mainly the...
diastolic blood pressure that was worth considering when diagnosing hypertension. The diastolic blood pressure was usually also the only blood pressure worthy of therapeutic intervention.

In recent years the systolic blood pressure has been presented as a stronger risk indicator than the diastolic blood pressure, not the least based on data from the Framingham Heart Study [11]. It could be argued that since the systolic blood pressure is at least as strong a risk indicator as the diastolic blood pressure [11], Moreover, intervention trials based on the level of systolic blood pressure such as SHEP [12], Syst-Eur [13] and Syst-China [14] have shown at least as good benefits of antihypertensive therapy on “hard endpoints” as studies based on diastolic blood pressure entry criteria.

In particular the impressive results shown in the intervention trials comprising patients with isolated systolic hypertension [12–14] have had a great impact on the present view on the importance of systolic blood pressure. It is also worth noting that the 1993 guidelines from WHO/ISH, for the first time listed systolic blood pressure criteria for the definition of hypertension [15]. This view is augmented in the most recent guidelines from WHO/ISH, issued in 1999, which also include definitions of isolated systolic hypertension and borderline isolated systolic hypertension (Table 2) [16]. That even borderline systolic hypertension leads to increased risks for stroke, coronary heart disease, congestive heart failure and other fatal or non-fatal cardiovascular events was clearly shown in a long-term follow-up from the Framingham Heart Study (Table 3) [17]. In a recent issue of “Blood Pressure”, another important aspect of systolic blood pressure was presented. Howes and coworkers showed that the prevalence of isolated systolic blood pressure in patients attending general practice in Australia is 8%, a percentage that can be expected to increase considerably with ageing [18]. Since most Westernized populations show that the proportion of elderly individuals increases it is to be expected that the management and treatment of systolic hypertension will assume greater importance in the future.

The significant impact of isolated systolic hypertension as a risk factor for cardiovascular morbidity and mortality was recently reviewed [19]. It was emphasised that the benefit of treating isolated systolic hypertension has been proven beyond doubt and that most likely also borderline isolated systolic hypertension, although not yet demonstrated in an appropriate prospective intervention trial, would benefit from treatment [19]. There may be many spin-offs from this. One could be that antihypertensive drugs that have been shown to be especially effective in lowering the systolic blood pressure will appear particularly attractive in the antihypertensive armamentarium.

### Table 1. Improvement of prognosis by antihypertensive therapy in non-malignant hypertension

<table>
<thead>
<tr>
<th>Authors</th>
<th>Number of patients</th>
<th>Year</th>
<th>Benefits shown at diastolic blood pressure &gt; (mm Hg)</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hamilton et al.</td>
<td>64</td>
<td>1964</td>
<td>110 (phase IV)</td>
<td>1</td>
</tr>
<tr>
<td>Wolff and Lindeman</td>
<td>87</td>
<td>1966</td>
<td>110</td>
<td>2</td>
</tr>
<tr>
<td>Veterans Administration</td>
<td>515</td>
<td>1967 &amp; 1970</td>
<td>105</td>
<td>3, 4</td>
</tr>
<tr>
<td>Australian National Study</td>
<td>3,943</td>
<td>1979</td>
<td>100</td>
<td>5</td>
</tr>
<tr>
<td>Australian National Study</td>
<td>3,427</td>
<td>1980</td>
<td>95</td>
<td>6</td>
</tr>
<tr>
<td>Hypertension Detection and</td>
<td>Follow-up Program</td>
<td>Study</td>
<td>10,940</td>
<td></td>
</tr>
<tr>
<td>Study</td>
<td>17,354</td>
<td>1985</td>
<td>90</td>
<td>8</td>
</tr>
</tbody>
</table>

### Table 2. Definitions and classification of blood pressure levels in the 1999 guidelines from the World Health Organization and the International Society of Hypertension

<table>
<thead>
<tr>
<th>Category</th>
<th>Systolic (mmHg)</th>
<th>Diastolic (mmHg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Optimal</td>
<td>&lt; 120</td>
<td>&lt; 80</td>
</tr>
<tr>
<td>Normal</td>
<td>&lt; 130</td>
<td>&lt; 85</td>
</tr>
<tr>
<td>High-normal</td>
<td>130–139</td>
<td>85–89</td>
</tr>
<tr>
<td>Hypertension</td>
<td>Grade 1 (mild)</td>
<td>140–159</td>
</tr>
<tr>
<td>Subgroup Borderline</td>
<td>140–149</td>
<td>90–94</td>
</tr>
<tr>
<td>Grade 2 (moderate)</td>
<td>160–179</td>
<td>100–109</td>
</tr>
<tr>
<td>Grade 3 (severe)</td>
<td>≥ 180</td>
<td>≥ 110</td>
</tr>
<tr>
<td>Isolated systolic hypertension</td>
<td>≥ 140</td>
<td>&lt; 90</td>
</tr>
<tr>
<td>Subgroup Borderline</td>
<td>140–149</td>
<td>&lt; 90</td>
</tr>
</tbody>
</table>

Based on [16]

### Table 3. Long-term cardiovascular morbidity and mortality in subjects who were free of cardiovascular disease at baseline in the Framingham Heart Study

<table>
<thead>
<tr>
<th>Events</th>
<th>Number of events</th>
<th>Normal Blood Pressure (n = 2416)</th>
<th>Borderline Isolated Systolic Hypertension (n = 351)</th>
<th>Hazard Ratio 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>All CV disease</td>
<td>821</td>
<td>818</td>
<td>189</td>
<td>1.47 (1.24–1.74)</td>
</tr>
<tr>
<td>CHD</td>
<td>557</td>
<td>553</td>
<td>125</td>
<td>1.44 (1.18–1.77)</td>
</tr>
<tr>
<td>Stroke or TIA</td>
<td>208</td>
<td>208</td>
<td>55</td>
<td>1.42 (1.03–1.94)</td>
</tr>
<tr>
<td>CHF</td>
<td>173</td>
<td>173</td>
<td>55</td>
<td>1.60 (1.15–2.22)</td>
</tr>
<tr>
<td>Fatal CV disease</td>
<td>316</td>
<td>313</td>
<td>102</td>
<td>1.57 (1.24–2.00)</td>
</tr>
<tr>
<td>All cause mortality</td>
<td>926</td>
<td>926</td>
<td>206</td>
<td>1.14 (0.97–1.34)</td>
</tr>
</tbody>
</table>

CV = cardiovascular, CHD = coronary heart disease, TIA = transient ischaemic attacks, CHF = congestive heart failure. From Sagie et al. 1993 [17].
Systolic Blood Pressure Control with Angiotensin II Receptor Blockade

Angiotensin II receptor antagonists of the AT1 subtype have been in clinical use since the mid-1990s. The new, highly selective AT1 receptor antagonist eprosartan is of special interest in this context since it also induces sympathetic suppression by inhibiting angiotensin II-stimulated presynaptic noradrenaline release [20]. In animal studies eprosartan has been shown to inhibit sympathetic outflow in contrast to several other AT1 receptor antagonists [21].

In an 8-week placebo-controlled dose-ranging study in 351 hypertensive patients, eprosartan at doses of 400, 600, 800 and 1200 mg daily was found to lower systolic blood pressure significantly at all doses [22]. Of particular importance is that eprosartan was found to be significantly more effective than enalapril in reducing systolic blood pressure in patients with severe hypertension (Figure 2) [23]. Eprosartan was also numerically, although not statistically, more effective in lowering the diastolic blood pressure [23].

African-American patients, a group of patients often considered to be relatively unresponsive to antihypertensive therapy based on the blockade of the renin-angiotensin-aldosterone system, have been found to respond especially well to eprosartan, the systolic blood pressure being reduced more in that patient group than in all other patients (Figure 3) [23].

Data of this kind indicate that angiotensin II receptor blockade with the AT1 receptor blocker eprosartan is very effective in lowering systolic blood pressure. This is of relevance in view of the established importance of systolic blood pressure as a risk indicator of cardiovascular morbidity and mortality.

References

4. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA 1970; 213: 1143–52.
Systolic Blood Pressure Control and Angiotensin II Antagonist Blockade

REVIEWS

J Clin Basic Cardiol 2001; 4: 134


Mitteilungen aus der Redaktion

Besuchen Sie unsere zeitschriftenübergreifende Datenbank

☑ Bilddatenbank  ☑ Artikeldatenbank  ☑ Fallberichte

e-Journal-Abo
Beziehen Sie die elektronischen Ausgaben dieser Zeitschrift hier.
Die Lieferung umfasst 4–5 Ausgaben pro Jahr zzgl. allfälliger Sonderhefte.
Unsere e-Journale stehen als PDF-Datei zur Verfügung und sind auf den meisten der marktüblichen e-Book-Readern, Tablets sowie auf iPad funktionsfähig.

☑ Bestellung e-Journal-Abo

Haftungsausschluss

Bitte beachten Sie auch diese Seiten:

Impressum  Disclaimers & Copyright  Datenschutzerklärung